Other · developed by Arcus Biosciences
AB102 is an agent administered orally, according to a trial registry entry, studied in healthy volunteers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07662057 | Phase 1 | Healthy Volunteers | Recruiting | RCUS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteers
Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.
See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RCUS catalysts and pipeline →